Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Barbazan, Jorge ^a   Dunkel, Ying ^b   Li, Hongying ^d   Nitsche, Ulrich ^c   Janssen, Klaus Peter ^c   Messer, Karen ^d   Ghosh, Pradipta ^b,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; CALCIUM BINDING PROTEIN; CALVASCULIN; CCDC88A PROTEIN, HUMAN; CCDC88C PROTEIN, HUMAN; DNA BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MACC1 PROTEIN, HUMAN; NERVE PROTEIN; NUCLEOBINDIN; S100A4 PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; TUMOR MARKER; VESICULAR TRANSPORT PROTEIN;

COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CALCIUM-BINDING PROTEINS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; GENE EXPRESSION; GTP-BINDING PROTEIN ALPHA SUBUNITS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROFILAMENT PROTEINS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NERVE TISSUE PROTEINS; PROTEIN STRUCTURE, TERTIARY; S100 CALCIUM-BINDING PROTEIN A4; TRANSCRIPTION FACTORS; VESICULAR TRANSPORT PROTEINS;

EID: 84959274602     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22112     Document Type: Article

References (64)

1. Dorsam, R. T. & Gutkind, J. S. G-protein-coupled receptors and cancer. Nat Rev Cancer 7, 79-94, doi: 10.1038/nrc2069 (2007).
2. O'Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 13, 412-424, doi: 10.1038/nrc3521 (2013).
3. Aznar, N., Kalogriopoulos, N., Midde, K. K., Lo, I. & Ghosh, P. Heterotrimeric G Protein Signaling via GIV/Girdin: Breaking the rules of engagement, space and time. BioEssays, Accepted, In Press (2015).
4. Garcia-Marcos, M., Ghosh, P. & Farquhar, M. G. GIV/Girdin transmits signals from multiple receptors by triggering trimeric G protein activation. J Biol Chem 290, 6697-6704, doi: 10.1074/jbc.R114.613414 (2015).
5. Ghosh, P. Heterotrimeric G proteins as emerging targets for network based therapy in cancer: End of a long futile campaign striking heads of a Hydra. Aging (Albany NY) 7, 469-474 (2015).
6. Ghosh, P. G protein coupled growth factor receptor tyrosine kinase: no longer an oxymoron. Cell Cycle 14, 2561-2565, doi: 10.1080/15384101.2015.1066538 (2015).
7. Ghosh, P., Garcia-Marcos, M. & Farquhar, M. G. GIV/Girdin is a rheostat that fine-tunes growth factor signals during tumor progression. Cell Adh Migr 5, 237-248 (2011).
8. Aznar, N. et al. Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling. Elife 4, e07091, doi: 10.7554/eLife.07091 (2015).
9. Garcia-Marcos, M., Kietrsunthorn, P. S., Wang, H., Ghosh, P. & Farquhar, M. G. G Protein binding sites on Calnuc (nucleobindin 1) and NUCB2 (nucleobindin 2) define a new class of G(alpha)i-regulatory motifs. J Biol Chem 286, 28138-28149, doi: 10.1074/jbc. M110.204099 (2011).
10. Sack, U. et al. S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 22, 3344-3354, doi: 10.1091/mbc.E10-09-0739 (2011).
11. Boye, K., Nesland, J. M., Sandstad, B., Maelandsmo, G. M. & Flatmark, K. Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer 46, 2919-2925, doi: 10.1016/j.ejca.2010.07.013 (2010).
12. Cho, Y. G. et al. Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 11, 4852-4856 (2005).
13. Gongoll, S. et al. Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123, 1478-1484 (2002).
14. Takenaga, K. Suppression of metastasis-associated S100A4 gene expression by gamma-interferon in human colon adenocarcinoma cells. Br J Cancer 80, 127-132, doi: 10.1038/sj.bjc.6690331 (1999).
15. Takenaga, K. et al. Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 3, 2309-2316 (1997).
16. Isella, C. et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg 257, 1089-1095, doi: 10.1097/SLA.0b013e31828f96bc (2013).
17. Stein, U. et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15, 59-67, doi: 10.1038/nm.1889 (2009).
18. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558, doi: 10.1126/science.1235122 (2013).
19. Overman, M. J. et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 31, 17-22, doi: 10.1200/JCO.2012.43.1718 (2013).
20. Plaks, V., Koopman, C. D. & Werb, Z. Cancer. Circulating tumor cells. Science 341, 1186-1188, doi: 10.1126/science.1235226 (2013).
21. Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31, 539-544, doi: 10.1038/nbt.2576 (2013).
22. Hodgkinson, C. L. et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20, 897-903, doi: 10.1038/nm.3600 (2014).
23. Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110-1122, doi: 10.1016/j.cell.2014.07.013 (2014).
24. Yu, M. et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216-220, doi: 10.1126/science.1253533 (2014).
25. Hayes, D. F. & Paoletti, C. Circulating tumour cells: insights into tumour heterogeneity. J Intern Med 274, 137-143, doi: 10.1111/joim.12047 (2013).
26. van Dalum, G. et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol 46, 1361-1368, doi: 10.3892/ijo.2015.2824 (2015).
27. Aggarwal, C. et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol 24, 420-428, doi: 10.1093/annonc/mds336 (2013).
28. Cohen, S. J. et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20, 1223-1229, doi: 10.1093/annonc/mdn786 (2009).
29. Cohen, S. J. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26, 3213-3221, doi: 10.1200/JCO.2007.15.8923 (2008).
30. Cohen, S. J. et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6, 125-132, doi: 10.3816/CCC.2006.n.029 (2006).
31. Barbazan, J. et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 135, 2633-2643, doi: 10.1002/ijc.28910 (2014).
32. Scher, H. I. et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castrationresistant prostate cancer. J Clin Oncol 33, 1348-1355, doi: 10.1200/JCO.2014.55.3487 (2015).
33. Miller, M. C., Doyle, G. V. & Terstappen, L. W. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010, 617421, doi: 10.1155/2010/617421 (2010).
34. Jiang, Z. F. et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Ann Oncol 24, 2766-2772, doi: 10.1093/annonc/mdt246 (2013).
35. Bednarz-Knoll, N., Alix-Panabieres, C. & Pantel, K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 13, 228, doi: 10.1186/bcr2940 (2011).
36. Kalikaki, A. et al. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PLoS One 9, e104902, doi: 10.1371/journal.pone.0104902 (2014).
37. Mohamed Suhaimi, N. A. et al. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol 9, 850-860, doi: 10.1016/j.molonc.2014.12.011 (2015).
38. Pestrin, M. et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 9, 749-757, doi: 10.1016/j.molonc.2014.12.001 (2015).
39. Markou, A. et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res 20, 5823-5834, doi: 10.1158/1078-0432.CCR-14-0149 (2014).
40. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359, 366-377, doi: 10.1056/NEJMoa0800668 (2008).
41. Lyberopoulou, A. et al. Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PLoS One 10, e0123902, doi: 10.1371/journal.pone.0123902 (2015).
42. Magbanua, M. J. et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 73, 30-40, doi: 10.1158/0008-5472.CAN-11-3017 (2013).
43. Punnoose, E. A. et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 5, e12517, doi: 10.1371/journal. pone.0012517 (2010).
44. Heitzer, E. et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73, 2965-2975, doi: 10.1158/0008-5472.CAN-12-4140 (2013).
45. Chiu, C. G. et al. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60, 873-885, doi: 10.1373/clinchem.2013.213611 (2014).
46. Yeh, C. S. et al. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol 28, 411-420 (2006).
47. Wang, J. Y. et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res 13, 2406-2413, doi: 10.1158/1078-0432.CCR-06-2054 (2007).
48. Gervasoni, A. et al. Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett 263, 267-279, doi: 10.1016/j.canlet.2008.01.003 (2008).
49. Barbazan, J. et al. Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS One 7, e40476, doi: 10.1371/journal.pone.0040476 (2012).
50. Gorges, T. M. et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 12, 178, doi: 10.1186/1471-2407-12-178 (2012).
51. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228-247, doi:10.1016/j.ejca.2008.10.026 (2009).
52. Barbazan, J. et al. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. J Cell Mol Med 16, 2342-2349, doi: 10.1111/j.1582-4934.2012.01544.x (2012).
53. Zhou, X. et al. Metastasis-Associated in Colon Cancer-1 Associates With Poor Prognosis and Promotes Cell Invasion and Angiogenesis in Human Cervical Cancer. Int J Gynecol Cancer 25, 1353-1363, doi: 10.1097/IGC.0000000000000524 (2015).
54. Sun, L. et al. Silence of MACC1 expression by RNA interference inhibits proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant glioma cells. Mol Med Rep 12, 3423-3431, doi: 10.3892/mmr.2015.3886 (2015).
55. Li, H. et al. The expression of MACC1 and its role in the proliferation and apoptosis of salivary adenoid cystic carcinoma. J Oral Pathol Med, doi: 10.1111/jop.12309 (2015).
56. Sun, L. et al. Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer. Cancer Lett 357, 242-253, doi: 10.1016/j.canlet.2014.11.035 (2015).
57. Sheng, X. J. et al. MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET. Oncol Lett 8, 891-897, doi: 10.3892/ol.2014.2184 (2014).
58. Zhen, T. et al. MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway. Oncotarget 5, 3756-3769 (2014).
59. Wang, Y., Hong, Q., Wang, J., Fang, Y. & Hu, C. Downregulated expression of metastasis associated in colon cancer 1 (MACC1) reduces gallbladder cancer cell proliferation and invasion. Tumour Biol 35, 3771-3778, doi: 10.1007/s13277-013-1499-z (2014).
60. Chai, H. & Yang, Y. Effects of MACC1 siRNA on biological behaviors of HeLa. Arch Gynecol Obstet 289, 1271-1280, doi: 10.1007/s00404-013-3126-z (2014).
61. Juneja, M., Ilm, K., Schlag, P. M. & Stein, U. Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol 7, 929-943, doi: 10.1016/j.molonc.2013.05.003 (2013).
62. Meng, F. et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling pathway. PLoS One 8, e60821, doi: 10.1371/journal.pone.0060821 (2013).
63. Wang, L. et al. Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion. Int J Cancer 133, 1419-1430, doi: 10.1002/ijc.28140 (2013).
64. Gao, J., Ding, F., Liu, Q. & Yao, Y. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem 376, 21-32, doi: 10.1007/s11010-012-1545-y (2013).